Myriad Genetics, Inc. (LON:0K3W)
7.24
-0.05 (-0.75%)
At close: Dec 5, 2025
Myriad Genetics Revenue
Myriad Genetics had revenue of $205.70M USD in the quarter ending September 30, 2025, a decrease of -3.56%. This brings the company's revenue in the last twelve months to $825.30M, up 0.21% year-over-year. In the year 2024, Myriad Genetics had annual revenue of $837.60M with 11.21% growth.
Revenue (ttm)
$825.30M
Revenue Growth
+0.21%
P/S Ratio
0.81
Revenue / Employee
$305.67K
Employees
2,700
Market Cap
496.03M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 837.60M | 84.40M | 11.21% |
| Dec 31, 2023 | 753.20M | 74.80M | 11.03% |
| Dec 31, 2022 | 678.40M | -12.20M | -1.77% |
| Dec 31, 2021 | 690.60M | 133.60M | 23.99% |
| Dec 31, 2020 | 557.00M | -81.60M | -12.78% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.24B |
| GSK plc | 32.17B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| Convatec Group | 1.72B |
| Spire Healthcare Group | 1.55B |
| Genus | 672.80M |
Myriad Genetics News
- 12 days ago - Myriad Genetics partners to use AI to measure breast cancer risk - Seeking Alpha
- 12 days ago - Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health - GlobeNewsWire
- 26 days ago - Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences - GlobeNewsWire
- 27 days ago - Myriad Genetics (MYGN) Broadens MyRisk Cancer Test with New Gene Inclusions - GuruFocus
- 4 weeks ago - Vanguard Group Inc Reduces Stake in Myriad Genetics Inc - GuruFocus
- 4 weeks ago - Myriad Genetics: Downgrading To "Hold" Rating On Break-Even Q3 Earnings - Seeking Alpha
- 4 weeks ago - TD Cowen Raises Myriad Genetics (MYGN) Price Target to $9.00 | MYGN Stock News - GuruFocus
- 4 weeks ago - Myriad Genetics Inc (MYGN) Q3 2025 Earnings Call Highlights: Navigating Revenue Decline with ... - GuruFocus